Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma
Part of paid clinical trials in Oklahoma City, Oklahoma.
- Sponsor
- University of Oklahoma
- Study ID
- NCT02241265
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Study Details
The investigators hypothesis is that there will be improvement in FEV1 in patients with severe asthma. This is a retrospective data study that reviews preexisting medical records; no patients will be enrolled.
Key Dates
- Start date
- Feb 28, 2014
- Status verified
- Feb 2025
- Primary completion
- Jan 31, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 20 participants (estimated)
Arms
- Arm: Past Bronchial Thermoplasty dataData will be collected from records of patients who, in the past, have undergone bronchial thermoplasty.
Primary Outcome Measure
The primary endpoints are improvements in prebronchodilator FEV1 and FVC. [ Time Frame: 1 year after thermoplasty ]
Central Contacts
- Brent Brown, MD405-271-6173
- Clinical Trials Manager
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| OUHSC | Oklahoma City | Oklahoma | 73104 | Brent Brown, MD 405-271-6173 Clinical Trials Manager Brent Brown, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Oklahoma City, OK
By condition
By specialty
By research site
Related Studies
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaPHASE3 · Recruiting · GlaxoSmithKline · Birmingham, Alabama
- A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaPHASE3 · Recruiting · AstraZeneca · Montgomery, Alabama
- Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaPHASE3 · Recruiting · AstraZeneca · Anchorage, Alaska
- Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaPHASE2 · Enrolling By Invitation · Sanofi · Chandler, Arizona